Beranda › Penyakit Neurologis › North Carolina
Uji klinis Penyakit Neurologis di North Carolina
7 studi untuk Penyakit Neurologis mencari peserta di lokasi di North Carolina.
Kota di North Carolina
Teks studi resmi (Bahasa Inggris)
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
- Denver, North Carolina, Denver
- Huntersville, North Carolina, Huntersville
Menerima pesertaFase 2/3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07598708Product Surveillance Registry
- Chapel Hill
- Charleston
- Durham
- dan 3 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT01524276A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Research Site, Chapel Hill
Menerima pesertaFase 1
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06916806A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
- Vima Site #067, Raleigh
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07804615A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- Duke University, Durham
Menerima pesertaFase 1
Usia 50 hingga 85 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06297590Rett Syndrome Registry
- The University of North Carolina at Chapel Hill, Chapel Hill
Menerima pesertaStudi observasional
Usia 0 hingga 99 · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT05432349Open-label Extension Study in Participants With Early Alzheimer's Disease
- GSK Investigational Site, Matthews
Menerima pesertaFase 2
Usia 50 hingga 85 · Semua jenis kelamin · Diperbarui 2 Feb 2026 · NCT07105709Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.